Comparative human and mouse antibody responses against tetanus toxin at clonal level

References

• Ahnert-Hilger, G., Bizzini, B., Goretzki, K., et al. 1983. Monoclonal antibodies against tetanus toxin and toxoid. Med. Microbiol. Immunol. 172:123–135
   PubMed Web of Science ®Google Scholar
• Anderson, R., Gao, X. M., Papakonstantinopoulou, A., et al. 1996. Immune response in mice following immunization with DNA encoding fragment C of tetanus toxin. Infect. Immun. 64:3168–3173
   PubMed Web of Science ®Google Scholar
• Arunachalam, B., Ghosh, S., Talwar, G., and Raghupathy, R. 1992. A single human monoclonal antibody that confers total protection from tetanus. Hybridoma 11:165–179
   PubMedGoogle Scholar
• Chaddock, J., and Marks, P. M. 2006. Clostridial neurotoxins: Structure-function led design of new therapeutics. Cell. Mol. Life Sci. 63:540–551
   PubMed Web of Science ®Google Scholar
• Cresswell, P. 1994. Assembly, transport, and function of MHC Class II molecules. Ann. Rev. Immunol. 12:259–291
   PubMed Web of Science ®Google Scholar
• di Tommaso, A., de Magistris, M. T., Bugnoli, M., et al. 1994. Formaldehyde treatment of proteins can constrain presentation to T-cells by limiting antigen processing. Infect. Immun. 62:1830–1834
   PubMed Web of Science ®Google Scholar
• Diethelm-Okita, B. M., Okita, D. K., Banaszak, L., and Conti-Fine, B. M. 2000. Universal epitopes for human CD4+ cells on tetanus and diphtheria toxins. J. Infect. Dis. 181:1001–1009
   PubMed Web of Science ®Google Scholar
• Diethelm-Okita, B. M., Raju, R., Okita, D. K., and Conti-Fine, B. M. 1997. Epitope repertoire of human CD4+ T-cells on tetanus toxin: Identification of immunodominant sequence segments. J. Infect. Dis. 175:382–391
   PubMed Web of Science ®Google Scholar
• Fitzsimmons, S. P., Clark, K. C., Wilkerson, R., and Shapiro, M. A. 2000. Inhibition of tetanus toxin fragment C binding to ganglioside GT1b by monoclonal antibodies recognizing different epitopes. Vaccine 19:114–121
   PubMed Web of Science ®Google Scholar
• Gigliotti, F., and Insel, R. 1982. Protective human hybridoma antibody to tetanus toxin. J. Clin. Invest. 70:1306–1309
   PubMed Web of Science ®Google Scholar
• Gustafsson, B., Whitmore, E., and Tiru, M. 1993. Neutralization of tetanus toxin by human monoclonal antibodies directed against tetanus toxin fragment C. Hybridoma 12:699–708
   PubMedGoogle Scholar
• Herreros, J., Lalli, G., Montecucco, C., and Schiavo, G. 2000. Tetanus toxin fragment C binds to a protein present in neuronal cell lines and motoneurons. J. Neurochem. 74:1941–1950
   PubMed Web of Science ®Google Scholar
• Ho, P. C., Mutch, D. A., Winkel, K. D., et al. 1990. Identification of two promiscuous T-cell epitopes from tetanus toxin. Eur. J. Immunol. 20:477–483
   PubMed Web of Science ®Google Scholar
• Ichimori, Y., Sasano, K., Itoh, H., et al. 1985. Establishment of hybridomas secreting human monoclonal antibodies against tetanus toxin and hepatitis B virus surface antigen. Biochem. Biophys. Res. Commun. 129:26–33
   PubMed Web of Science ®Google Scholar
• Kamei, M., Hashizume, S., Sugimoto, N., et al. 1990. Establishment of stable mouse/human-human hybrid cell lines producing large amounts of anti-tetanus human monoclonal antibodies with high neutralizing activity. Eur. J. Epidemiol. 6:386–397
   PubMed Web of Science ®Google Scholar
• Kazemi, T., Tahmasebi, F., Bayat, A. A., et al. 2011. Characterization of novel murine monoclonal antibodies directed against extracellular domain of human HER2 tyrosine kinase receptor. Hybridoma 30:347–353
   PubMedGoogle Scholar
• Kenimer, J. G., Habig, W. H., and Hardegree, M. C. 1983. Monoclonal antibodies as probes of tetanus toxin structure and function. Infecti. Immun. 42:942–948
   PubMed Web of Science ®Google Scholar
• King, C. A., Spellerberg, M. B., Zhu, D., et al. 1998. DNA vaccines with single-chain Fv fused to fragment C of tetanus toxin induce protective immunity against lymphoma and myeloma. Nature Med. 4:1281–1286
   PubMed Web of Science ®Google Scholar
• Kitchin, N. R. 2011. Review of diphtheria, tetanus and pertussis vaccines in clinical development. Expert Rev. Vaccines 10:605–615
   PubMed Web of Science ®Google Scholar
• Kozbor, D., Roder, J. C., Chang, T. H., et al. 1982. Human anti-tetanus toxoid monoclonal antibody secreted by EBV-transformed human B-cells fused with murine myeloma. Hybridoma 1:323–328
   PubMed Web of Science ®Google Scholar
• Lalli, G., Bohnert, S., Deinhardt, K., et al. 2003. The journey of tetanus and botulinum neurotoxins in neurons. Trends Microbiol. 11:431–437
   PubMed Web of Science ®Google Scholar
• Lang, A., Cryz, S., Schurch, U., et al. 1993. Immunotherapy with human monoclonal antibodies. Fragment A specificity of polyclonal and monoclonal antibodies is crucial for full protection against tetanus toxin. J. Immunol. 151:466–472
   PubMed Web of Science ®Google Scholar
• Larrick, J. W., Truitt, K. E., Raubitschek, A. A., et al. 1983. Characterization of human hybridomas secreting antibody to tetanus toxoid. Proc. Natl. Acad. Sci. USA 80:6376–6380
   PubMed Web of Science ®Google Scholar
• Luo, P., Qin, L., Mao, X., et al. 2012. Identification of a novel linear epitope in tetanus toxin recognized by a protective monoclonal antibody: Implications for vaccine design. Vaccine 30:6449–6455
   PubMed Web of Science ®Google Scholar
• Madden, D.R. 1995. The three-dimensional structure of peptide-MHC complexes. Ann. Rev. Immunol. 13:587–622
   PubMed Web of Science ®Google Scholar
• Matsuda, M., Kamei, M., Sugimoto, N., et al. 1992. Characteristics of toxin-neutralization by anti-tetanus human monoclonal antibodies directed against the three functional domains [A], [B], and [C] of the tetanus toxin molecule and a reliable method for evaluating the protective effects of monoclonal antibodies. Eur. J. Epidemiol. 8:1–8
   PubMed Web of Science ®Google Scholar
• Mayer, S., Laumer, M., Mackensen, A., et al. 2002. Analysis of the immune response against tetanus toxoid: Enumeration of specific T-helper cells by ELISPOT assay. Immunobiology 205:282–289
   PubMed Web of Science ®Google Scholar
• Montecucco, C., and Schiavo, G. 2006. Mechanism of action of tetanus and botulinum neurotoxins. Mol. Microbiol. 13:1–8
   Web of Science ®Google Scholar
• Petrušić, V., Živković, I., Stojanović, M., et al. 2011. Production, characterization and applications of a tetanus toxin specific monoclonal antibody T-62. Acta Histochemica 114:480–486
   PubMed Web of Science ®Google Scholar
• Poulsen, T. R., Meijer, P. J., Jensen, A., et al. 2007. Kinetic, affinity, and diversity limits of human polyclonal antibody responses against tetanus toxoid. J. Immunol. 179:3841–3850
   PubMed Web of Science ®Google Scholar
• Reece, J. C., Geysen, H. M., and Rodda, S. J. 1993. Mapping the major human T-helper epitopes of tetanus toxin. The emerging picture. J. Immunol. 151:6175–6184
   PubMed Web of Science ®Google Scholar
• Robinson, K., Chamberlain, L., Lopez, M., et al. 2004. Mucosal and cellular immune responses elicited by recombinant Lactococcus lactis strains expressing tetanus toxin fragment C. Infect. Immun. 72:2753–2761
   PubMed Web of Science ®Google Scholar
• Schiavo, G., Matteoli, M., and Montecucco, C. 2000. Neurotoxins affecting neuroexocytosis. Physiol. Rev. 80:717–766
   PubMed Web of Science ®Google Scholar
• Sheppard, A. J., Cussell, D., and Hughes, M. 1984. Production and characterization of monoclonal antibodies to tetanus toxin. Infect. Immun. 43:710–714
   PubMed Web of Science ®Google Scholar
• Simpson, L. L., Lake, P., and Kozaki, S. 1990. Isolation and characterization of a novel human monoclonal antibody that neutralizes tetanus toxin. J. Pharmacol. Exp. Ther. 254:98–103
   PubMed Web of Science ®Google Scholar
• Trabaud, M. A., Lery, L., and Desgranges, C. 1989. Human monoclonal antibodies with a protective activity against tetanus toxin. APMIS 97:671–676
   PubMed Web of Science ®Google Scholar
• Turton, K., Chaddock, J. A., and Acharya, K. R. 2002. Botulinum and tetanus neurotoxins: Structure, function and therapeutic utility. Trends Biochem. Sci. 27:552–558
   PubMed Web of Science ®Google Scholar
• Volk, W., Bizzini, B., Snyder, R., et al. 1984. Neutralization of tetanus toxin by distinct monoclonal antibodies binding to multiple epitopes on the toxin molecule. Infect. Immun. 45:604–609
   PubMed Web of Science ®Google Scholar
• Volkman, D., Allyn, S., and Fauci, A. 1982. Antigen-induced in vitro antibody production in humans: Tetanus toxoid-specific antibody synthesis. J. Immunol. 129:107–112
   PubMed Web of Science ®Google Scholar
• Watts, C. 1997. Capture and processing of exogenous antigens for presentation on MHC molecules. Ann. Rev. Immunol. 15:821–850
   PubMed Web of Science ®Google Scholar
• Younesi, V., Nikzamir, H., Yousefi, M., et al. 2010. Epstein Barr virus inhibits the stimulatory effect of TLR7/8 and TLR9 agonists but not CD40 ligand in human B-lymphocytes. Microbiol. Immunol. 54:534–541
   PubMed Web of Science ®Google Scholar
• Younesi, V., Shirazi, F. G., Memarian, A., et al. 2014. Assessment of the effect of TLR7/8, TLR9 agonists and CD40 ligand on the transfor–mation efficiency of Epstein-Barr virus in human B-lymphocytes by limiting dilution assay. Cytotechnology 66:95–105
   PubMed Web of Science ®Google Scholar
• Yousefi, M., Khosravi-Eghbal, R., Hemmati, A., and Shokri, F. 2013a. Production and characterization of recombinant light chain and carboxyl terminal heavy chain fragments of tetanus toxin. Avicenna J. Med. Biotech. 5:220–226
   PubMedGoogle Scholar
• Yousefi, M., Khosravi-Eghbal, R., Mahmoudi, A. R., et al. 2013b. Comparative in vitro and in vivo assessment of toxin neutralization by anti-tetanus toxin monoclonal antibodies. Human Vaccines Immunother. 10:16–15
   Web of Science ®Google Scholar
• Yousefi, M., Tahmasebi, F., Younesi, V., et al. 2014. Characterization of neutralizing monoclonal antibodies directed against tetanus toxin fragment C. J. Immunotoxicol. 11:28–34
   PubMed Web of Science ®Google Scholar